Areas where scientific evidence is lacking or incomplete.
The TRAVERSE trial provided high-quality MACE data over a median of 33 months. Cardiovascular disease and prostate pathologies develop over decades. No study has tracked TU outcomes beyond 5 years with the rigour of TRAVERSE. Assuming permanent safety based on 3-year data may lead to under-monitoring of patients on continuous therapy for 10 or more years.
Implications: Ageing patients on long-term TU may develop latent complications (subclinical cardiac remodelling, slow-growing prostate pathology) that 33-month trial follow-up cannot detect. The gap is especially relevant for men who start TU in their 40s and remain on therapy for decades.
Testosterone regulates structural brain changes during late adolescence, including cortical thinning in frontoparietal regions and prefrontal-amygdala connectivity. Most TU data is extrapolated from cohorts of men over 40. No longitudinal neuroimaging studies have tracked young hypogonadal men receiving TU compared to age-matched controls.
Implications: Medical practitioners may inadvertently disrupt critical neurodevelopmental trajectories in young men. The evidence quality for neurodevelopmental impact is ranked as low or insufficient, based on small observational studies rather than controlled trials.
Current comparisons between TU and peptides like Kisspeptin-10 (for testosterone stimulation) or Tesamorelin (for visceral fat reduction) are purely mechanistic. No multi-arm randomised controlled trials compare the two approaches on shared clinical endpoints.
Implications: Patients choose between TU and peptides based on mechanism-of-action reasoning rather than comparative outcome data. A patient who selects Kisspeptin-10 over TU (or vice versa) is making a decision that no trial has validated.
Clinical trials exclusively use therapeutic doses (750 to 1,000 mg IM or 158 to 237 mg oral BID). Performance-enhancement contexts involve significantly higher amounts. The safety profile of therapeutic TU cannot be assumed to apply to supraphysiological levels.
Implications: If safety is assumed at higher doses without data, users face unknown risks for organ toxicity, behavioural changes, and severe erythrocytosis that are not observed in clinical settings. This is a data-free zone.
General timelines suggest sperm recovery takes 6 to 24 months after cessation. Advancing age is associated with slower and potentially less complete restoration. No study provides precise age-stratified data mapping how recovery capacity diminishes by decade of life.
Implications: Older men may overestimate their axis recovery capacity and delay fertility planning. Recovery protocols (hCG, FSH, SERMs) are applied without age-specific dosing evidence.
Pharmaceutical labelling for Aveed and Jatenzo explicitly states that safety and efficacy for 'age-related hypogonadism' have not been established. Despite this, widespread clinical use for age-related decline continues off-label without dedicated regulatory oversight.
Implications: Extensive off-label prescribing proceeds without the safety scrutiny that an on-label indication would require. Side effects unique to ageing populations (as distinct from classical hypogonadism) may be masked by the assumption that the same safety profile applies.
Water retention is a noted side effect of oral TU (incidence greater than 2%), but clinical data on the mechanistic causes and precise resolution timeline is sparse. It is unclear whether TU-induced edema is transient (resolving within weeks) or persistent during therapy.
Implications: Patients may prematurely discontinue therapy or receive unnecessary diuretics because the natural resolution period for TU-induced edema is not well defined in the literature.
Expert disagreements and competing evidence.
High-dose testosterone is inherently linked to increased aggression, paranoia, and 'roid rage.'
Community observation and studies of anabolic-androgenic steroid abusers frequently report mania and aggression.
Source: AAS abuse literature
Testosterone Undecanoate does not significantly increase aggressive behaviour in healthy men when administered in controlled settings.
Double-blind, placebo-controlled trials using high therapeutic doses (e.g. 1,000 mg IM) showed no increase in anger or aggressive behaviour.
Source: Controlled clinical trials
Verdict Note
While abuse of multiple AAS compounds is linked to psychiatric issues, rigorous clinical trials focusing specifically on TU at therapeutic levels consistently fail to replicate the 'roid rage' phenomenon. However, Jatenzo carries a specific safety signal for worsening mood, depression, and suicidal ideation, which is distinct from the aggression question.
Resolution
Large-scale observational studies of community users who use only high-dose TU (isolated from other steroids) with standardised psychological testing.
Erythrocytosis is a rare side effect affecting a very small percentage of TU users.
An 84-week clinical study of Aveed reported high hematocrit in only 1.3% of patients. Kyzatrex clinical trials reported 0%.
Source: Aveed Phase III trial, Kyzatrex clinical program
Erythrocytosis is a common and significant risk for men on TRT.
A retrospective study of TRT patients found that 23% reached hematocrit levels above 0.50.
Source: Retrospective TRT cohort analysis
Verdict Note
The disparity (0% to 1.3% vs 23%) likely reflects different population baselines, age groups, delivery methods (oral vs injectable), and hematocrit thresholds used to define the condition. The 0% Kyzatrex finding is from a single trial program and requires confirmation. Route of administration may be the key variable: lymphatic absorption avoids the supraphysiological spike that drives erythropoiesis.
Resolution
A prospective, multi-centre longitudinal study tracking hematocrit levels across different TU delivery methods (oral vs injectable) and age groups, using standardised thresholds.
TU is a validated therapy for restoring physiological testosterone levels in ageing men with symptomatic decline.
Dose-ranging studies in ageing men (mean age often 45+) show improvements in lean mass, bone density, and libido.
Source: Clinical trial data and practice guidelines
The safety and efficacy of TU for age-related hypogonadism are not established.
FDA-approved labelling for Aveed and Jatenzo explicitly states that safety and efficacy for age-related hypogonadism have not been established.
Source: Prescribing Information (Aveed, Jatenzo)
Verdict Note
This is a structural conflict between clinical practice and regulatory labelling standards. Clinical data demonstrates efficacy in older populations, but the FDA maintains a conservative position on the definition of treatable hypogonadism. The practical result: widespread off-label prescribing continues without the regulatory scrutiny an on-label indication would require.
Resolution
Long-term (5+ year) Phase IV trials specifically targeting men with functional age-related decline rather than organic pathology, designed to satisfy FDA efficacy and safety criteria.
Testosterone therapy causes direct cardiac toxicity and structural remodelling.
AAS abuse and misuse are linked to direct hypertrophic cardiomyopathy and cardiac arrest.
Source: AAS abuse case series
Cardiac risks from TU are indirect, primarily driven by blood pressure elevation and secondary arrhythmias.
The TRAVERSE trial showed MACE non-inferiority but identified increased atrial fibrillation (3.5%) and blood pressure elevation (1.7 to 5 mmHg).
Source: TRAVERSE trial
Verdict Note
Direct toxicity is primarily observed in extreme abuse scenarios involving multiple compounds at supraphysiological doses. Large-scale clinical evidence (TRAVERSE) points toward hemodynamic changes (BP elevation) and rhythm disturbances (AF) as the actual clinical risks at therapeutic TU levels.
Resolution
Cardiac MRI studies on therapeutic TU users to detect subclinical structural changes versus hemodynamic markers over several years of continuous therapy.
Testosterone administration in young adults carries high-confidence risks of permanent neurological alteration.
Testosterone regulates cortical thinning and prefrontal-amygdala connectivity during late adolescence.
Source: Neurodevelopmental research
Risks to brain structure in this age group are largely theoretical.
Evidence quality for neurodevelopmental impact is ranked as low or insufficient, based on small observational studies.
Source: Evidence quality reviews
Verdict Note
A clear divergence exists between known biological mechanisms (testosterone's documented role in brain structure maturation) and the absence of clinical evidence showing permanent harm in this specific age group treated with TU. The precautionary principle favours caution, but the claim of 'permanent neurological alteration' exceeds what the current data can confirm.
Resolution
Longitudinal neuroimaging studies of young hypogonadal men receiving TRT compared to age-matched controls, with cognitive and emotional outcome tracking over 5+ years.